Skip to main content

Agilent and Groton to Co-Market HPLC-Integrated Tool in North America

NEW YORK (GenomeWeb News) — Agilent Technologies and Groton Biosystems will co-market Groton’s Process Analytic Technology to pharmaceutical companies in North America, the companies said today.
 
PAT integrates Agilent’s 1200 series high-performance liquid chromatography instrument with Groton’s online sampling products and services. The tool is designed to help drug makers design, analyze, and control how raw and in-process materials are manufactured, the companies said. 
 
As part of the deal the firms will market the tools at trade shows, customer events, and product presentations, the companies said. 
 
The companies also said they expect in the “near future” to expand the agreement to Europe and Asia.
 
Financial terms of the agreement were not released.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.